Supplement encyclopedia

Inositol family

Inositols are a group of related compounds; myo-inositol and D-chiro-inositol are among those studied.

Double-check the conclusions and read the sources before choosing a supplement.

Main conclusion

What it may offer

  • In one study of women aged 18–35 with PCOS and overweight or obesity who were taking metformin, a regular cycle after six months was reported by 19 of 24 women taking a myo- and D-chiro-inositol mixture and 15 of 24 taking metformin alone. These numbers do not allow a confident conclusion that adding the mixture helped restore regular cycles more often.
  • In women with PCOS and obesity, a possible benefit of D-chiro-inositol is more frequent ovulation: during 6–8 weeks at 1200 mg daily, ovulation was recorded in 19 of 22 women, versus 6 of 22 on placebo.
  • Inofolic with myo-inositol and folic acid may improve semen parameters in men younger than 45 with infertility of unknown cause. After three months, sperm concentration was 26.4 versus 20.8 million/ml, and progressive motility was 27.6% versus 23.3% with sachets containing folic acid alone.

[1] [2] [3]

What was studied

  • The cycle and ovulation findings come from two studies of women with PCOS; choosing a formulation on this basis means considering this specific group and the metformin use in the mixture trial.
  • One study in men with infertility of unknown cause assessed sperm count, concentration, motility and acrosome reaction; the expected benefit of the studied combination concerns these semen parameters.

[1] [2] [3]

Which forms were considered

  • In PCOS, D-chiro-inositol alone and a myo- and D-chiro-inositol mixture alongside metformin were studied; the exact composition matters when choosing a product, rather than just the word “inositol” on the package.
  • The men's study used myo-inositol with folic acid, so the reported semen changes apply to this combination.

[1] [2] [3] [4]

How to get it from food

  • Inositol can be obtained from fruit, legumes, grains and nuts; for example, per 100 g the food table lists 355 mg of total myo-inositol in fresh melon and 307 mg in orange.
  • The food values include bound forms broken down during laboratory analysis; these numbers cannot be used to calculate a dose of free myo-inositol from a supplement.

[1]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Regular menstrual cycleIn one study, a regular cycle at month six was reported in 19 of 24 with the supplement and 15 of 24 with metformin alone.By month six, 19/24 versus 15/24; p<0.001 refers to the analysis of changes over time, not this direct comparison.
1/4 Very lowEstimate precision: Small groups and no CI for the direct effect. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Adjunct comparison of a mixture; cannot be transferred to a single isomer. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Five of 53 were not included in the cycle-regularity denominators; blinding is unconfirmed.
11 trialA randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome ↗53 women aged 18–35 with PCOS and overweight or obesity; 26/27 randomized
  1. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome ↗
Ovulation assessed by progesteroneOver 6–8 weeks, ovulation was recorded in 19 of 22 women taking D-chiro-inositol and 6 of 22 on placebo.19/22 versus 6/22, p<0.001.
2/4 LowEstimate precision: A small study or confidence interval leaves substantial uncertainty. Consistency of findings: A single comparison; consistency cannot be assessed. Applicability to the specified group: The result was measured in the specified restricted group. Possible publication bias: No specific data; bias cannot be ruled out. Study methods: Small study, incomplete description of methods or selective reporting of results.
11 trialOvulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗44 women with PCOS and obesity; 22 in each group
  1. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗
Systolic and diastolic blood pressureIn the D-chiro-inositol group of women with PCOS and obesity, both blood pressure measures fell by 4 mmHg from baseline over 6–8 weeks.Within-group change with D-chiro-inositol: systolic and diastolic pressure fell by 4 mmHg; this is not the size of the between-group difference.
1/4 Very lowEstimate precision: A small study or confidence interval leaves substantial uncertainty. Consistency of findings: A single comparison; consistency cannot be assessed. Applicability to the specified group: Restricted group, biomarker or combination product. Possible publication bias: No specific data; bias cannot be ruled out. Study methods: Small study, incomplete description of methods or selective reporting of results.
11 trialOvulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗44 women with PCOS and obesity; 22 in each group
  1. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextInformation
Intake and studied regimensStudies used 1200 mg D-chiro-inositol daily, a mixture of 1.1 g myo-inositol and 27.6 mg D-chiro-inositol twice daily alongside metformin, or 2 g myo-inositol with 200 µg folic acid twice daily. These are doses from specific trials, not a single dose for all forms.

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗

Forms

Myo-inositol and D-chiro-inositol are different isomers. Results for one formulation cannot automatically be transferred to another.

Guidance for each goal

Regular menstrual cycle1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: Small groups and no CI for the direct effect. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Adjunct comparison of a mixture; cannot be transferred to a single isomer. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Five of 53 were not included in the cycle-regularity denominators; blinding is unconfirmed.

In one study, a regular cycle at month six was reported in 19 of 24 with the supplement and 15 of 24 with metformin alone.

Study findings. In one study, a regular cycle at month six was reported in 19 of 24 with the supplement and 15 of 24 with metformin alone.

Studied regimen1.1 g + 27.6 mg twice daily; metformin 500 mg twice dailyMyo-inositol + D-chiro-inositol alongside metformin
Duration and population6 months53 women aged 18–35 with PCOS and overweight or obesity; 26/27 randomized

Comparison: Metformin 500 mg twice daily

Ovulation assessed by progesterone2/4 LowRead moreCollapse
Confidence
2/4 LowEstimate precision: A small study or confidence interval leaves substantial uncertainty. Consistency of findings: A single comparison; consistency cannot be assessed. Applicability to the specified group: The result was measured in the specified restricted group. Possible publication bias: No specific data; bias cannot be ruled out. Study methods: Small study, incomplete description of methods or selective reporting of results.

Over 6–8 weeks, ovulation was recorded in 19 of 22 women taking D-chiro-inositol and 6 of 22 on placebo.

Study findings. Over 6–8 weeks, ovulation was recorded in 19 of 22 women taking D-chiro-inositol and 6 of 22 on placebo.

Studied regimen1200 mg once dailyOral D-chiro-inositol
Duration and population6–8 weeks44 women with PCOS and obesity; 22 in each group

Comparison: Placebo

Systolic and diastolic blood pressure1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: A small study or confidence interval leaves substantial uncertainty. Consistency of findings: A single comparison; consistency cannot be assessed. Applicability to the specified group: Restricted group, biomarker or combination product. Possible publication bias: No specific data; bias cannot be ruled out. Study methods: Small study, incomplete description of methods or selective reporting of results.

In the D-chiro-inositol group of women with PCOS and obesity, both blood pressure measures fell by 4 mmHg from baseline over 6–8 weeks.

Study findings. In the D-chiro-inositol group of women with PCOS and obesity, both blood pressure measures fell by 4 mmHg from baseline over 6–8 weeks.

Studied regimen1200 mg once dailyOral D-chiro-inositol
Duration and population6–8 weeks44 women with PCOS and obesity; 22 in each group

Comparison: Placebo

Plasma triglycerides1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: A small study or confidence interval leaves substantial uncertainty. Consistency of findings: A single comparison; consistency cannot be assessed. Applicability to the specified group: Restricted group, biomarker or combination product. Possible publication bias: No specific data; bias cannot be ruled out. Study methods: Small study, incomplete description of methods or selective reporting of results.

In the same study, triglycerides fell from 184 to 110 mg/dl in the D-chiro-inositol group over 6–8 weeks.

Study findings. In the same study, triglycerides fell from 184 to 110 mg/dl in the D-chiro-inositol group over 6–8 weeks.

Studied regimen1200 mg once dailyOral D-chiro-inositol
Duration and population6–8 weeks44 women with PCOS and obesity; 22 in each group

Comparison: Placebo

Sperm concentration1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: No CI for the direct contrast. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Laboratory measure; the control group's folate dose is unconfirmed. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Completeness of the analysis is unknown.

After three months, sperm concentration was 26.4 versus 20.8 million/ml in the myo-inositol plus folic acid and folic acid alone groups.

Study findings. After three months, sperm concentration was 26.4 versus 20.8 million/ml in the myo-inositol plus folic acid and folic acid alone groups.

Studied regimen2 g myo-inositol + 200 µg folic acid per sachet, two sachets dailyInofolic sachets: myo-inositol + folic acid
Duration and population3 months194 men younger than 45 with idiopathic infertility; 98/96 by group

Comparison: Folic acid sachets twice daily

Total sperm count1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: No CI for the direct contrast. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Laboratory measure; the control group's folate dose is unconfirmed. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Completeness of the analysis is unknown.

After three months, total sperm count was 57.6 versus 47.8 million per ejaculate.

Study findings. After three months, total sperm count was 57.6 versus 47.8 million per ejaculate.

Studied regimen2 g myo-inositol + 200 µg folic acid per sachet, two sachets dailyInofolic sachets: myo-inositol + folic acid
Duration and population3 months194 men younger than 45 with idiopathic infertility; 98/96 by group

Comparison: Folic acid sachets twice daily

Progressive motility1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: No CI for the direct contrast. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Laboratory measure; the control group's folate dose is unconfirmed. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Completeness of the analysis is unknown.

After three months, progressive motility was 27.6% versus 23.3%.

Study findings. After three months, progressive motility was 27.6% versus 23.3%.

Studied regimen2 g myo-inositol + 200 µg folic acid per sachet, two sachets dailyInofolic sachets: myo-inositol + folic acid
Duration and population3 months194 men younger than 45 with idiopathic infertility; 98/96 by group

Comparison: Folic acid sachets twice daily

Acrosome reaction1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowEstimate precision: No CI for the direct contrast. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: Laboratory measure; the control group's folate dose is unconfirmed. Possible publication bias: No specific data supporting a separate downgrade. Study methods: Completeness of the analysis is unknown.

After three months, the acrosome reaction was 41% versus 36%.

Study findings. After three months, the acrosome reaction was 41% versus 36%.

Studied regimen2 g myo-inositol + 200 µg folic acid per sachet, two sachets dailyInofolic sachets: myo-inositol + folic acid
Duration and population3 months194 men younger than 45 with idiopathic infertility; 98/96 by group

Comparison: Folic acid sachets twice daily

Reported pregnancies1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowrisk_of_bias: Five of 53 were not included in the cycle-regularity denominators; blinding is unconfirmed. inconsistency: No grounds for a separate downgrade. indirectness: Adjunct comparison of a mixture; cannot be transferred to a single isomer. imprecision: Small groups and no CI for the direct effect. publication_bias: No specific data supporting a separate downgrade.

Over six months, three pregnancies were reported in each group; no added benefit of the inositol mixture was shown.

Study findings. Over six months, three pregnancies were reported in each group; no added benefit of the inositol mixture was shown.

Studied regimen1.1 g myo-inositol + 27.6 mg D-chiro-inositol twice daily; metformin 500 mg twice dailyMyo-inositol + D-chiro-inositol alongside metformin
Duration and population6 months53 women aged 18–35 with PCOS and overweight or obesity, 26/27 randomized; denominators for the pregnancy analysis are not separately confirmed

Reported events; equivalence of effectiveness and effects on live birth have not been established. Comparison: Metformin 500 mg twice daily

Oral glucose tolerance test1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowrisk_of_bias: Small study, incomplete methods or selective outcomes inconsistency: Single comparison; consistency not assessable indirectness: Restricted population, biomarker or mixed preparation imprecision: Small trial or confidence interval covers important uncertainty publication_bias: No specific evidence, not excluded

Over 6–8 weeks of D-chiro-inositol use in women with PCOS and obesity, no significant change in glucose tolerance was found on the oral test.

Study findings. Over 6–8 weeks of D-chiro-inositol use in women with PCOS and obesity, no significant change in glucose tolerance was found on the oral test.

Studied regimen1200 mg once dailyOral D-chiro-inositol
Duration and population6–8 weeks44 women with PCOS and obesity; 22 randomized to each group

Narrow descriptive oral-test result. p=0.07 refers to the comparison of changes in insulin AUC and is not assigned to glucose here. Comparison: Placebo

Safety and limitations

In a review of PCOS trials, gastrointestinal adverse events were less frequent with myo-inositol than metformin in the main analysis; the result was unstable when restricted to studies at low risk of bias. Adverse events were not reported in 23 of 29 trials. In a six-week study of 17 people with bipolar depression taking lithium or valproate, in 2 of 9 in the inositol group, depression worsened by more than 50% on the HRSD; the abstract does not provide a comparable control count. Causality and risk frequency are unknown. In a study of 464 pregnant women with PCOS taking myo-inositol 2 g and folic acid 0.2 mg twice daily, adverse events were reported by 6.9% versus 9.1% with folic acid alone (RR 0.76; 95% CI 0.40–1.45). This does not establish the safety of all doses and forms during pregnancy. The 2023 PCOS guideline does not establish a single preferred inositol form, dose or combination; the results here are tied to specific products and groups.

Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines ↗ · Inositol augmentation of lithium or valproate for bipolar depression ↗ · Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial ↗ · Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome ↗

Food sources

The table shows total myo-inositol measured after acid hydrolysis, including bound forms; this is not a separate measurement of free or absorbed inositol. Values refer to the samples studied, not a supplement dose. Energy is given for comparable USDA foods.

Fruit and dried fruit

Myo-inositol was detected in tested samples of melon, citrus fruit, other fruit and dried fruit.

Myo-inositol content of common foods: development of a high-myo-inositol diet ↗

Legumes

Myo-inositol was detected in tested samples of beans and other legumes.

Myo-inositol content of common foods: development of a high-myo-inositol diet ↗

Bread and grains

Myo-inositol was detected in the grain products tested.

Myo-inositol content of common foods: development of a high-myo-inositol diet ↗

Nuts and spreads

Myo-inositol was detected in tested samples of nuts and peanut butter.

Myo-inositol content of common foods: development of a high-myo-inositol diet ↗

Vegetables

Myo-inositol was detected in the vegetable samples tested.

Myo-inositol content of common foods: development of a high-myo-inositol diet ↗

Food composition

FoodGroupAmountServingCaloriesSources
Cantaloupe melonfresh fleshFruit355 mg total myo-inositol after hydrolysis / 100 g100 g · 355 mg total myo-inositol after hydrolysis · 34 kcalEdible-portion weight selected for comparison; values calculated on this basis.34 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Orangefresh edible portionFruit307 mg total myo-inositol after hydrolysis / 100 g100 g · 307 mg total myo-inositol after hydrolysis · 47 kcalEdible-portion weight selected for comparison; values calculated on this basis.47 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Limefresh edible portionFruit194 mg total myo-inositol after hydrolysis / 100 g100 g · 194 mg total myo-inositol after hydrolysis · 30 kcalEdible-portion weight selected for comparison; values calculated on this basis.30 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Nectarinefresh edible portionFruit118 mg total myo-inositol after hydrolysis / 100 g100 g · 118 mg total myo-inositol after hydrolysis · 44 kcalEdible-portion weight selected for comparison; values calculated on this basis.44 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Mangofresh fleshFruit99 mg total myo-inositol after hydrolysis / 100 g100 g · 99 mg total myo-inositol after hydrolysis · 60 kcalEdible-portion weight selected for comparison; values calculated on this basis.60 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Pearfresh edible portionFruit73 mg total myo-inositol after hydrolysis / 100 g100 g · 73 mg total myo-inositol after hydrolysis · 57 kcalEdible-portion weight selected for comparison; values calculated on this basis.57 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Watermelonfresh fleshFruit31 mg total myo-inositol after hydrolysis / 100 g200 g · 62 mg total myo-inositol after hydrolysis · 60 kcalEdible-portion weight selected for comparison; values calculated on this basis.30 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Pineapplefresh fleshFruit33 mg total myo-inositol after hydrolysis / 100 g100 g · 33 mg total myo-inositol after hydrolysis · 50 kcalEdible-portion weight selected for comparison; values calculated on this basis.50 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
PrunesdriedDried fruit470 mg total myo-inositol after hydrolysis / 100 g20 g · 94 mg total myo-inositol after hydrolysis · 48 kcalEdible-portion weight selected for comparison; values calculated on this basis.240 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Fruits and Fruit Juices ↗
Peanutsraw, shelledNuts133 mg total myo-inositol after hydrolysis / 100 g15 g · 19.95 mg total myo-inositol after hydrolysis · 85.05 kcalEdible-portion weight selected for comparison; values calculated on this basis.567 kcal / 100 gMyo-inositol content of common foods: development of a high-myo-inositol diet ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Legumes and Legume Products ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome ↗Regular menstrual cycle; Reported pregnancies53 women aged 18–35 with PCOS and overweight or obesity; 26/27 randomizedMyo-inositol + D-chiro-inositol alongside metformin; 1.1 g + 27.6 mg twice daily; metformin 500 mg twice daily; 6 months; comparison: Metformin 500 mg twice dailyIn one study, a regular cycle at month six was reported in 19 of 24 with the supplement and 15 of 24 with metformin alone. Over six months, three pregnancies were reported in each group; no added benefit of the inositol mixture was shown.
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome ↗Ovulation assessed by progesterone: Ovulation assessed by progesterone Systolic and diastolic blood pressure: Systolic and diastolic blood pressure Plasma triglycerides: Plasma triglycerides; Oral glucose tolerance testOvulation assessed by progesterone: 44 women with PCOS and obesity; 22 in each group Systolic and diastolic blood pressure: 44 women with PCOS and obesity; 22 in each group Plasma triglycerides: 44 women with PCOS and obesity; 22 in each groupOvulation assessed by progesterone: Oral D-chiro-inositol; 1200 mg once daily; 6–8 weeks; comparison: Placebo Systolic and diastolic blood pressure: Oral D-chiro-inositol; 1200 mg once daily; 6–8 weeks; comparison: Placebo Plasma triglycerides: Oral D-chiro-inositol; 1200 mg once daily; 6–8 weeks; comparison: PlaceboOvulation assessed by progesterone: Over 6–8 weeks, ovulation was recorded in 19 of 22 women taking D-chiro-inositol and 6 of 22 on placebo. Systolic and diastolic blood pressure: In the D-chiro-inositol group of women with PCOS and obesity, both blood pressure measures fell by 4 mmHg from baseline over 6–8 weeks. Plasma triglycerides: In the same study, triglycerides fell from 184 to 110 mg/dl in the D-chiro-inositol group over 6–8 weeks. Over 6–8 weeks of D-chiro-inositol use in women with PCOS and obesity, no significant change in glucose tolerance was found on the oral test.